Provided by Tiger Trade Technology Pte. Ltd.

Vor Biopharma Inc.

14.56
-0.4950-3.29%
Volume:389.28K
Turnover:5.63M
Market Cap:604.32M
PE:-0.04
High:15.15
Open:14.95
Low:14.04
Close:15.05
52wk High:65.80
52wk Low:2.62
Shares:41.52M
Float Shares:18.97M
Volume Ratio:0.57
T/O Rate:2.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-386.8600
EPS(LYR):-34.0333
ROE:-125.43%
ROA:-144.27%
PB:-0.27
PE(LYR):-0.43

Loading ...

Vor Bio says telitacicept shows sustained efficacy in China Phase 3 study

TIPRANKS
·
Oct 29, 2025

Vor Biopharma Reports Telitacicept Achieves Sustained Efficacy in Phase 3 Myasthenia Gravis Trial

Reuters
·
Oct 29, 2025

Vor Biopharma Inc - 100% Patients on Telitacicept Achieve ≥2-Point Mg-Adl Improvement

THOMSON REUTERS
·
Oct 29, 2025

Vor Biopharma Inc - Telitacicept Shows Favorable Profile Compared to Placebo

THOMSON REUTERS
·
Oct 29, 2025

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

THOMSON REUTERS
·
Oct 29, 2025

Vor Biopharma Inc - No Injection Site Reactions in Telitacicept Patients

THOMSON REUTERS
·
Oct 29, 2025

Corrected-Vor Biopharma Inc. : H.c. Wainwright Raises Target Price to $55(Not $52) From $3 to Reflect 1-for-20 Reverse Stock Split (Clarifies PT Is Split-Adjusted)

THOMSON REUTERS
·
Oct 29, 2025

Vor Biopharma Unveils Promising Phase 3 Trial Results

TIPRANKS
·
Oct 29, 2025

Peter Kolchinsky, Director, Reports Disposal of Vor Biopharma Inc. Common Shares

Reuters
·
Oct 28, 2025

Major Moves: Fifth Third, HEICO, Transdigm, Cytokinetics, Vor Biopharma

TIPRANKS
·
Oct 25, 2025

RA Capital Management Reports Disposal of Vor Biopharma Common Shares

Reuters
·
Oct 23, 2025

Major Shareholder Offloads Thousands of Vor Biopharma Shares!

TIPRANKS
·
Oct 22, 2025

Reprogrammed Interchange LLC Reports Disposal of Vor Biopharma Inc. Common Shares

Reuters
·
Oct 22, 2025

Major Vor Biopharma Stock Sales by Key Shareholders!

TIPRANKS
·
Oct 18, 2025

RA Capital Management Reports Sale of Vor Biopharma Inc. Common Shares

Reuters
·
Oct 18, 2025

Vor Biopharma Announces Positive Phase 3 Results for Telitacicept in IgA Nephropathy; Data to Be Presented at ASN Kidney Week 2025

Reuters
·
Oct 17, 2025

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 Iga Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025

THOMSON REUTERS
·
Oct 17, 2025

Vor Biopharma Announces Positive Phase 3 Trial Results for Telitacicept in Lupus, Published in NEJM

Reuters
·
Oct 16, 2025

Major Stakeholder Sells Big on Vor Biopharma!

TIPRANKS
·
Oct 16, 2025

Reprogrammed Interchange LLC Reports Disposal of Common Shares of Vor Biopharma Inc

Reuters
·
Oct 16, 2025